Agon USA, Inc. – Trademark Portfolio

Entity Type: 03

Agon USA, Inc. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 3 filings in this category. The portfolio also extends into Class 18 (Leather Goods) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include AGON and COZYVEST. The owner is based in New York, NY.

#1V

350 E 30th St.

New York, NY 10016

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

COZYVEST
COZYVEST
Registered 2018
COZYFUR
COZYFUR
Abandoned 2018
AGON
AGON
Registered 2017
A
A
Cancelled 2017

Trademark Classifications

Agon USA, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (3 filings)

Surgical, medical, dental and veterinary apparatus and instruments

18
Leather Goods (1 filing)

Leather and imitations of leather; animal skins, hides; trunks and travelling bags

Frequently Asked Questions

How many trademarks does Agon USA, Inc. have?

Agon USA, Inc. has 4 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned, 1 cancelled.

What trademark classes does Agon USA, Inc. file in?

Agon USA, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 18 (Leather Goods). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are Agon USA, Inc.'s most well-known trademarks?

Agon USA, Inc.'s registered trademark portfolio includes well-known marks such as AGON and COZYVEST. These are among 2 currently registered trademarks in the portfolio.

What is Agon USA, Inc.'s trademark registration success rate?

Agon USA, Inc. has a 50% trademark registration rate, with 2 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.